Hugo is about to joust da Vinci. It’s not a battle between Renaissance geniuses. Instead, a commercial fight is brewing ...

Ryan Weispfenning has elected to take up the challenge of creating and leading the investor relations function at the planned ...

Medtronic plc is rated a Buy, expecting 10-11% annual total returns, supported by 7-8% EPS growth. Learn more about MDT stock ...

Medtronic's fair value estimate has nudged higher to $111.05 from $109.82 as analysts grow more confident that the company ...

That is, if you can handle more volatility.

Medtronic announced the first commercial use of the Liberant thrombectomy system, which is indicated for the removal of fresh, ...

Liberant is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous ...

Weispfenning has more than 25 years of experience at Medtronic, joining its IR team 17 years ago. He led the function at the ...

With the U.S. authorization for urologic procedures, “there is now choice” for hospitals that want to expand their robotic ...

Though the Medtronic OmniaSecure is the world's smallest defibrillation lead, the product development story isn't one of ...

Medtronic issues recall diabetes software affecting CareLink version 4.2B due to incorrect glucose data display, prompting clinician review.

Medtronic's Hugo surgical robot gained FDA clearance for urologic procedures, opening U.S. market entry and setting the stage ...